These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16787244)

  • 1. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections.
    Bregenholt S; Jensen A; Lantto J; Hyldig S; Haurum JS
    Curr Pharm Des; 2006; 12(16):2007-15. PubMed ID: 16787244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogen-specific recombinant human polyclonal antibodies: biodefence applications.
    Bregenholt S; Haurum J
    Expert Opin Biol Ther; 2004 Mar; 4(3):387-96. PubMed ID: 15006732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recombinant monoclonal antibodies for the treatment and prevention of viral infections].
    Al'khovskiĭ SV
    Vestn Ross Akad Med Nauk; 2011; (5):49-53. PubMed ID: 21786598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New technologies in therapeutic antibody development: The next frontier for treating infectious diseases.
    Keating SM; Higgins BW
    Antiviral Res; 2024 Jul; 227():105902. PubMed ID: 38734210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies for the prevention and treatment of viral diseases.
    Sawyer LA
    Antiviral Res; 2000 Aug; 47(2):57-77. PubMed ID: 10996394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant polyclonal antibodies: therapeutic antibody technologies come full circle.
    Haurum J; Bregenholt S
    IDrugs; 2005 May; 8(5):404-9. PubMed ID: 15883923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies for biodefense.
    Froude JW; Stiles B; Pelat T; Thullier P
    MAbs; 2011; 3(6):517-27. PubMed ID: 22123065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive antibody administration (immediate immunity) as a specific defense against biological weapons.
    Casadevall A
    Emerg Infect Dis; 2002 Aug; 8(8):833-41. PubMed ID: 12141970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
    Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.
    Mejias A; Garcia-Maurino C; Rodriguez-Fernandez R; Peeples ME; Ramilo O
    Vaccine; 2017 Jan; 35(3):496-502. PubMed ID: 27692523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing infectious disease with passive immunization.
    Zeitlin L; Cone RA; Moench TR; Whaley KJ
    Microbes Infect; 2000 May; 2(6):701-8. PubMed ID: 10884621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antiviral humanized and human monoclonal antibodies].
    Lashkevich VA
    Vopr Virusol; 2011; 56(5):4-8. PubMed ID: 22171470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manufacture of recombinant polyclonal antibodies.
    Rasmussen SK; Rasmussen LK; Weilguny D; Tolstrup AB
    Biotechnol Lett; 2007 Jun; 29(6):845-52. PubMed ID: 17310321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human monoclonal antibody Fab fragments cloned from combinatorial libraries: potential usefulness in prevention and/or treatment of major human viral diseases.
    Chanock RM; Crowe JE; Murphy BR; Burton DR
    Infect Agents Dis; 1993 Jun; 2(3):118-31. PubMed ID: 8173784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Passive immunotherapy of viral infections: 'super-antibodies' enter the fray.
    Walker LM; Burton DR
    Nat Rev Immunol; 2018 May; 18(5):297-308. PubMed ID: 29379211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1.
    Jaworski JP; Cahn P
    Lancet HIV; 2018 Dec; 5(12):e723-e731. PubMed ID: 30245003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of recombinant human polyclonal antibodies for the treatment of complex human diseases.
    Tolstrup AB; Frandsen TP; Bregenholt S
    Expert Opin Biol Ther; 2006 Sep; 6(9):905-12. PubMed ID: 16918257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vector-Mediated In Vivo Antibody Expression.
    Schnepp BC; Johnson PR
    Microbiol Spectr; 2014 Aug; 2(4):AID-0016-2014. PubMed ID: 26104192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in Mice.
    Wohlbold TJ; Chromikova V; Tan GS; Meade P; Amanat F; Comella P; Hirsh A; Krammer F
    J Virol; 2016 Jan; 90(2):851-61. PubMed ID: 26512088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of camelid heavy-chain variable domains (VHHs) in prevention and treatment of bacterial and viral infections.
    Wilken L; McPherson A
    Int Rev Immunol; 2018 Jan; 37(1):69-76. PubMed ID: 29182399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.